← Back to Search

Shared Decision Making for Chronic Kidney Disease (DIAL-SDM Trial)

N/A
Waitlist Available
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 12 months
Awards & highlights

DIAL-SDM Trial Summary

This trial is testing a dialysis shared decision-making (DIAL-SDM) intervention for nephrologists and their patients ≥65 years old with an estimated glomerular filtration rate (eGFR) of ≤ 20 ml/min/ /1.73 m2. The intervention includes communication training and coaching sessions for patients (and caregivers, if available) to explore each patient's relevant contextual information (values, preferences, and goals), and help them identify and practice important questions for their nephrologist. The study outcomes will be assessed during two nephrology office visits and at 6 months.

Who is the study for?
This trial is for patients aged 65 or older with advanced chronic kidney disease (stages 4 or 5) who haven't yet decided on dialysis and speak English. Their nephrologist must be part of the study and working at Strong Memorial Hospital. Caregivers involved in patient care can also participate.Check my eligibility
What is being tested?
The trial tests a shared decision-making program (DIAL-SDM) against usual care for kidney disease treatment choices. Nephrologists will get communication training, while patients receive coaching to help them discuss their treatment preferences effectively.See study design
What are the potential side effects?
Since this intervention involves education and communication rather than medication, there are no direct medical side effects; however, participants may experience emotional or psychological impacts from discussing sensitive health decisions.

DIAL-SDM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
acceptability of DIAL-SDM intervention
feasibility of DIAL-SDM intervention
Interventional procedure

DIAL-SDM Trial Design

2Treatment groups
Experimental Treatment
Group I: interventionExperimental Treatment1 Intervention
Group II: controlExperimental Treatment1 Intervention
Usual care

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
845 Previous Clinical Trials
534,957 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,720 Previous Clinical Trials
7,494,167 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,376 Previous Clinical Trials
4,315,707 Total Patients Enrolled

Media Library

DIAL-SDM Clinical Trial Eligibility Overview. Trial Name: NCT04392440 — N/A
Chronic Kidney Disease Research Study Groups: intervention, control
Chronic Kidney Disease Clinical Trial 2023: DIAL-SDM Highlights & Side Effects. Trial Name: NCT04392440 — N/A
DIAL-SDM 2023 Treatment Timeline for Medical Study. Trial Name: NCT04392440 — N/A
~18 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top